AR085501A1 - ANTICUERPO ANTI-TNF a HUMANIZADO - Google Patents
ANTICUERPO ANTI-TNF a HUMANIZADOInfo
- Publication number
- AR085501A1 AR085501A1 ARP120100640A ARP120100640A AR085501A1 AR 085501 A1 AR085501 A1 AR 085501A1 AR P120100640 A ARP120100640 A AR P120100640A AR P120100640 A ARP120100640 A AR P120100640A AR 085501 A1 AR085501 A1 AR 085501A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- sequence
- antibody
- tnf
- humanized anti
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- AIDS & HIV (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Anticuerpo monoclonal anti-TNF humanizado y su uso. El anticuerpo monoclonal anti-TNF humanizado reduce significativamente la inmunogenicidad de anticuerpos de murinos reteniendo al mismo tiempo la capacidad del anticuerpo para reconocer al antígeno, en comparación con un anticuerpo quimérico conservador de ratón. De esta manera se mejora la seguridad del anticuerpo para las aplicaciones clínicas.Reivindicación 1: Un anticuerpo monoclonal anti-TNF humanizado, caracterizado porque comprende una cadena pesada y una cadena liviana, en donde la cadena pesada tiene la secuencia de la SEQ ID Nº 1 o una secuencia al menos un 75% homóloga de la SEQ ID Nº 1, y la cadena liviana tiene la secuencia de la SEQ ID Nº 2 o una secuencia al menos un 75% homóloga de la SEQ ID Nº 2.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110048505 | 2011-02-28 | ||
CN201210026698.5A CN102675460B (zh) | 2011-02-28 | 2012-02-07 | 抗肿瘤坏死因子α的人源化抗体 |
PCT/CN2012/071079 WO2012116595A1 (zh) | 2011-02-28 | 2012-02-13 | 抗肿瘤坏死因子α的人源化抗体 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR085501A1 true AR085501A1 (es) | 2013-10-09 |
Family
ID=46757361
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP120100640A AR085501A1 (es) | 2011-02-28 | 2012-02-28 | ANTICUERPO ANTI-TNF a HUMANIZADO |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP2682405A4 (es) |
JP (2) | JP6054864B2 (es) |
KR (1) | KR101576559B1 (es) |
CN (1) | CN102675460B (es) |
AR (1) | AR085501A1 (es) |
AU (1) | AU2012222738B2 (es) |
BR (1) | BR112013021860A2 (es) |
CA (1) | CA2827799C (es) |
RU (1) | RU2549700C1 (es) |
WO (1) | WO2012116595A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103217489B (zh) | 2013-01-15 | 2016-03-09 | 珠海市丽珠单抗生物技术有限公司 | 一种测定蛋白纯化工艺过程中样品的糖基化和末端修饰情况的方法 |
WO2015190439A1 (ja) * | 2014-06-09 | 2015-12-17 | 株式会社カネカ | 抗体に結合する低分子化合物のスクリーニング方法 |
KR102571700B1 (ko) | 2016-03-17 | 2023-08-29 | 누맙 세러퓨틱스 아게 | 항TNFα 항체 및 이의 기능성 단편 |
CN106279413A (zh) * | 2016-08-30 | 2017-01-04 | 苏州普罗达生物科技有限公司 | 抗肿瘤坏死因子抗体多肽及应用 |
CN111153994B (zh) * | 2019-12-31 | 2021-10-15 | 武汉班科生物技术股份有限公司 | 人肿瘤坏死因子的人源单克隆抗体 |
CN115819575B (zh) * | 2022-08-24 | 2023-06-27 | 武汉爱博泰克生物科技有限公司 | 针对人肿瘤坏死因子-α的单克隆抗体 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4818679A (en) | 1985-02-19 | 1989-04-04 | The Trustees Of Columbia University In The City Of New York | Method for recovering mutant cells |
US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
DE3631229A1 (de) | 1986-09-13 | 1988-03-24 | Basf Ag | Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung |
GB9109645D0 (en) * | 1991-05-03 | 1991-06-26 | Celltech Ltd | Recombinant antibodies |
DE07012625T1 (de) | 1991-03-18 | 2010-01-21 | New York University | Monoklonale und chimäre Antikörper gegen humanen Tumornekrosefaktor |
US5919452A (en) | 1991-03-18 | 1999-07-06 | New York University | Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies |
UA81743C2 (uk) * | 2000-08-07 | 2008-02-11 | Центокор, Инк. | МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ |
CN1585778A (zh) * | 2001-11-12 | 2005-02-23 | 默克专利有限公司 | 修饰的抗-TNFα抗体 |
US20030206898A1 (en) * | 2002-04-26 | 2003-11-06 | Steven Fischkoff | Use of anti-TNFalpha antibodies and another drug |
CN1225479C (zh) * | 2002-12-23 | 2005-11-02 | 马菁 | 肿瘤坏死因子抗体,其制备方法以及药物组合物 |
CN1255536C (zh) | 2003-11-13 | 2006-05-10 | 中国人民解放军第四军医大学 | 高亲和力抗肿瘤坏死因子单克隆抗体的可变区基因及其制备 |
KR100772800B1 (ko) | 2003-11-17 | 2007-11-01 | 주식회사유한양행 | 인간 종양괴사인자 α를 인식하는 단일클론항체의가변영역 및 이를 코딩하는 유전자 |
CA2577133A1 (en) * | 2004-08-19 | 2006-03-23 | Genentech, Inc. | Polypeptide variants with altered effector function |
US7645450B2 (en) * | 2004-12-29 | 2010-01-12 | Yuhan Corporation | Humanized antibody specific for tumor necrosis factor-alpha |
CN101177453B (zh) * | 2006-11-07 | 2010-09-29 | 旭华(上海)生物研发中心有限公司 | 抗人肿瘤坏死因子α的重组嵌合抗体 |
ES2411907T3 (es) * | 2007-08-03 | 2013-07-09 | Facet Biotech Corporation | Uso terapéutico de anticuerpos antirreceptor TWEAK |
EP2050764A1 (en) * | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
AU2009213738B2 (en) * | 2008-02-11 | 2015-01-22 | Curetech Ltd. | Monoclonal antibodies for tumor treatment |
-
2012
- 2012-02-07 CN CN201210026698.5A patent/CN102675460B/zh active Active
- 2012-02-13 CA CA2827799A patent/CA2827799C/en not_active Expired - Fee Related
- 2012-02-13 JP JP2013516997A patent/JP6054864B2/ja active Active
- 2012-02-13 EP EP12752672.1A patent/EP2682405A4/en not_active Withdrawn
- 2012-02-13 BR BR112013021860-6A patent/BR112013021860A2/pt not_active Application Discontinuation
- 2012-02-13 RU RU2013139480/10A patent/RU2549700C1/ru active IP Right Revival
- 2012-02-13 KR KR1020137025433A patent/KR101576559B1/ko active IP Right Grant
- 2012-02-13 WO PCT/CN2012/071079 patent/WO2012116595A1/zh active Application Filing
- 2012-02-13 AU AU2012222738A patent/AU2012222738B2/en active Active
- 2012-02-28 AR ARP120100640A patent/AR085501A1/es unknown
-
2015
- 2015-07-03 JP JP2015134436A patent/JP2016006052A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CA2827799C (en) | 2017-03-21 |
AU2012222738A1 (en) | 2013-08-22 |
JP6054864B2 (ja) | 2016-12-27 |
EP2682405A4 (en) | 2015-06-24 |
RU2549700C1 (ru) | 2015-04-27 |
AU2012222738B2 (en) | 2016-05-26 |
EP2682405A1 (en) | 2014-01-08 |
CN102675460A (zh) | 2012-09-19 |
CA2827799A1 (en) | 2012-09-07 |
BR112013021860A2 (pt) | 2018-09-11 |
JP2016006052A (ja) | 2016-01-14 |
RU2013139480A (ru) | 2015-04-10 |
CN102675460B (zh) | 2015-08-19 |
KR101576559B1 (ko) | 2015-12-10 |
KR20130133272A (ko) | 2013-12-06 |
JP2013539354A (ja) | 2013-10-24 |
WO2012116595A1 (zh) | 2012-09-07 |
NZ615477A (en) | 2015-11-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2564252T3 (es) | Anticuerpos anti-péptido beta-amiloide N3pGlu y usos de los mismos | |
ES2687282T3 (es) | Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos | |
AR099812A1 (es) | Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr | |
AR106184A1 (es) | Proteínas de unión a pd-1 y sus métodos de uso | |
AR085501A1 (es) | ANTICUERPO ANTI-TNF a HUMANIZADO | |
ES2620264T3 (es) | Anticuerpos humanizados frente a LIV-1 y el uso de los mismos para tratar el cáncer | |
PE20180042A1 (es) | Anticuerpos anti-ox40 y metodos de uso de los mismos | |
AR084141A1 (es) | Anticuerpos neutralizadores anti-ccl20 | |
MX341958B (es) | Anticuerpos contra el il33r humano y usos de los mismos. | |
AR096617A1 (es) | Anticuerpos anti-tweakr y sus usos | |
AR102698A1 (es) | Anticuerpos contra cd73 y sus usos | |
PE20141568A1 (es) | Anticuerpos humanizados que reconocen la alfa-sinucleina | |
ES2621874T3 (es) | Anticuerpos para MUC16 y métodos de uso de los mismos | |
PE20181054A1 (es) | Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion | |
AR082518A1 (es) | Anticuerpos contra il-18r1 y usos de los mismos | |
AR098465A1 (es) | ANTICUERPOS ANTI-a-SINUCLEÍNA Y MÉTODOS DE UTILIZACIÓN | |
ES2670621T3 (es) | Anticuerpos que se unen a OX40 y sus usos | |
ES2584956T3 (es) | Anticuerpos anti-CD40 y usos de los mismos | |
CO6430469A2 (es) | Anticuerpos humanizados que se unen a cd19 y sus usos | |
AR096687A1 (es) | Anticuerpos anti-fcrh5 | |
PE20150002A1 (es) | Anticuerpos anti-fcrn | |
AR083747A1 (es) | Anticuerpos anti-il-23 | |
AR084315A1 (es) | Anticuerpos anti-notch1 | |
PE20091024A1 (es) | Anticuerpos monoclonales que se unen a anexelekto y sus usos | |
PE20141147A1 (es) | Anticuerpos a pcsk9 y usos de los mismos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |